181 related articles for article (PubMed ID: 28790822)
1. Complement C3-dependent uptake of targeted liposomes into human macrophages, B cells, dendritic cells, neutrophils, and MDSCs.
Francian A; Mann K; Kullberg M
Int J Nanomedicine; 2017; 12():5149-5161. PubMed ID: 28790822
[TBL] [Abstract][Full Text] [Related]
2. Intratumoral delivery of antigen with complement C3-bound liposomes reduces tumor growth in mice.
Francian A; Namen S; Stanley M; Mann K; Martinson H; Kullberg M
Nanomedicine; 2019 Jun; 18():326-335. PubMed ID: 30419362
[TBL] [Abstract][Full Text] [Related]
3. Complement C3 mediated targeting of liposomes to granulocytic myeloid derived suppressor cells.
Kullberg M; Martinson H; Mann K; Anchordoquy TJ
Nanomedicine; 2015 Aug; 11(6):1355-63. PubMed ID: 25839391
[TBL] [Abstract][Full Text] [Related]
4. Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
Seledtsov VI; Goncharov AG; Seledtsova GV
Hum Vaccin Immunother; 2015; 11(4):851-69. PubMed ID: 25933181
[TBL] [Abstract][Full Text] [Related]
5. Contribution of long-chain fatty acid to induction of myeloid-derived suppressor cell (MDSC)-like cells - induction of MDSC by lipid vesicles (liposome).
Yoshida Y; Nagamori T; Ishibazawa E; Kobayashi H; Kure T; Sakai H; Takahashi D; Fujihara M; Azuma H
Immunopharmacol Immunotoxicol; 2020 Dec; 42(6):614-624. PubMed ID: 33070657
[TBL] [Abstract][Full Text] [Related]
6. Delivery of TLR7 agonist to monocytes and dendritic cells by DCIR targeted liposomes induces robust production of anti-cancer cytokines.
Klauber TCB; Laursen JM; Zucker D; Brix S; Jensen SS; Andresen TL
Acta Biomater; 2017 Apr; 53():367-377. PubMed ID: 28153581
[TBL] [Abstract][Full Text] [Related]
7. Delivery of toll-like receptor agonists by complement C3-targeted liposomes activates immune cells and reduces tumour growth.
Francian A; Widmer A; Olsson T; Ramirez M; Heald D; Rasic K; Adams L; Martinson H; Kullberg M
J Drug Target; 2021 Aug; 29(7):754-760. PubMed ID: 33472457
[TBL] [Abstract][Full Text] [Related]
8. Antigen presenting cell-selective drug delivery by glycan-decorated nanocarriers.
Frenz T; Grabski E; Durán V; Hozsa C; Stępczyńska A; Furch M; Gieseler RK; Kalinke U
Eur J Pharm Biopharm; 2015 Sep; 95(Pt A):13-7. PubMed ID: 25701806
[TBL] [Abstract][Full Text] [Related]
9. Mediation of a non-proteolytic activation of complement component C3 by phospholipid vesicles.
Klapper Y; Hamad OA; Teramura Y; Leneweit G; Nienhaus GU; Ricklin D; Lambris JD; Ekdahl KN; Nilsson B
Biomaterials; 2014 Apr; 35(11):3688-96. PubMed ID: 24462362
[TBL] [Abstract][Full Text] [Related]
10. Resiquimod, a TLR7/8 agonist, promotes differentiation of myeloid-derived suppressor cells into macrophages and dendritic cells.
Lee M; Park CS; Lee YR; Im SA; Song S; Lee CK
Arch Pharm Res; 2014; 37(9):1234-40. PubMed ID: 24748512
[TBL] [Abstract][Full Text] [Related]
11. Suppressive role of myeloid-derived suppressor cells (MDSCs) in the microenvironment of breast cancer and targeted immunotherapies.
Shou D; Wen L; Song Z; Yin J; Sun Q; Gong W
Oncotarget; 2016 Sep; 7(39):64505-64511. PubMed ID: 27542274
[TBL] [Abstract][Full Text] [Related]
12. Enhancing T Cell and Antibody Response in Mucin-1 Transgenic Mice through Co-Delivery of Tumor-Associated Mucin-1 Antigen and TLR Agonists in C3-Liposomes.
Arabi A; Aria Soltani S; Maniaci B; Mann K; Martinson H; Kullberg M
Pharmaceutics; 2023 Dec; 15(12):. PubMed ID: 38140114
[TBL] [Abstract][Full Text] [Related]
13. Liposome-based immunity-inducing systems for cancer immunotherapy.
Yuba E
Mol Immunol; 2018 Jun; 98():8-12. PubMed ID: 29128232
[TBL] [Abstract][Full Text] [Related]
14. Immunostimulatory and antigen delivery properties of liposomes made up of total polar lipids from non-pathogenic bacteria leads to efficient induction of both innate and adaptive immune responses.
Faisal SM; Chen JW; McDonough SP; Chang CF; Teng CH; Chang YF
Vaccine; 2011 Mar; 29(13):2381-91. PubMed ID: 21300103
[TBL] [Abstract][Full Text] [Related]
15. Myeloid cells as a target for oligonucleotide therapeutics: turning obstacles into opportunities.
Kortylewski M; Moreira D
Cancer Immunol Immunother; 2017 Aug; 66(8):979-988. PubMed ID: 28214929
[TBL] [Abstract][Full Text] [Related]
16. Immature mouse granulocytic myeloid cells are characterized by production of ficolin-B.
Weber-Steffens D; Hunold K; Kürschner J; Martinez SG; Elumalai P; Schmidt D; Trevani A; Runza VL; Männel DN
Mol Immunol; 2013 Dec; 56(4):488-96. PubMed ID: 23911405
[TBL] [Abstract][Full Text] [Related]
17. MPLA incorporation into DC-targeting glycoliposomes favours anti-tumour T cell responses.
Boks MA; Ambrosini M; Bruijns SC; Kalay H; van Bloois L; Storm G; Garcia-Vallejo JJ; van Kooyk Y
J Control Release; 2015 Oct; 216():37-46. PubMed ID: 26151293
[TBL] [Abstract][Full Text] [Related]
18. [Role of the complement C3 protein in the control of the specific immune response].
Villiers CL; Villiers MB; Marche PN
Ann Biol Clin (Paris); 1999; 57(2):127-35. PubMed ID: 10210739
[TBL] [Abstract][Full Text] [Related]
19. Complement dependent and independent liposome uptake by peritoneal macrophages: cholesterol content dependency.
Huong TM; Harashima H; Kiwada H
Biol Pharm Bull; 1998 Sep; 21(9):969-73. PubMed ID: 9781849
[TBL] [Abstract][Full Text] [Related]
20. Self, non-self, and danger: a complementary view.
Köhl J
Adv Exp Med Biol; 2006; 586():71-94. PubMed ID: 16893066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
